Pierre Fabre Laboratories acquires Vertical Bio and its innovative targeted therapy for MET-altered Non-Small Cell Lung Cancer patients
French-based pharmaceutical and dermo-cosmetic business, Pierre Fabre Laboratories, disclosed the purchase of Vertical Bio AG, a firm specializing in innovative cancer treatments. With this premier purchase of a biotech enterprise, Pierre Fabre Laboratories can now integrate VERT-002 into its cancer research development process.
👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.
VERT-002, a unique monoclonal antibody operating as a c-MET degrader, presents an innovative approach to its mode of action. This target has shown to be a key driver of disease in individuals affected by Non-Small Cell Lung Cancer with MET mutations or amplification. Although the specifics of the agreement were not revealed, Vertical Bio, initiated by Versant Ventures, came into existence through the firm's Ridgeline Discovery Engine stationed in Basel, Switzerland.
With the aid of Ridgeline's biological competencies, Vertical Bio managed to progress VERT-002 through the pre-clinical phase and towards an IND submission. The commencement of first-in-human trials is anticipated around 2024.
Within the context of this purchase, Pierre Fabre Laboratories has the opportunity to bolster their precision oncology R&D portfolio with a prospective clinical development product. In adherence to its progressive strategy, the company has prioritized cancer research within the medical sector, directing approximately 80% of its yearly R&D investment towards this field. As a testament to its success, the Oncology Franchise posted a revenue of 467 M€ in 2022, evidence of a sharp 221% compared to the 2019 revenues.
Expressing his contentment about the newfound partnership, Eric Ducournau, the Chief Executive Officer of Pierre Fabre Laboratories stated, "We see the acquisition of this biotechnology firm and the inclusion of VERT-002 as an opportunity to further enhance our R&D endeavors in the domain of lung cancer. This acquisition emphasizes our dedication towards contributing to the invention and process of formulating advanced therapies in the domain of precision oncology."
👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.
According to the data provided by the Synapse Database, As of September 17, 2023, there are 167 investigational drugs for the c-Met target, including 153 applicable indications,224 R&D institutions involved, with related clinical trials reaching 1147，and as many as 20326 patents.
The success of VERT-002 in clinical trials and subsequent regulatory approvals will determine its potential as a valuable treatment option for NSCLC patients and potentially other neoplasms and respiratory diseases. VERT-002 is currently completing IND-enabling studies and Vertical Bio expects to begin first in human studies in 2024.
